AGC Biologics, a global CDMO, has appointed Jean-Baptiste Agnus as the company’s Chief Business Officer (CBO), responsible for strategic leadership over all aspects of the company’s global business development and sales and marketing teams.
 
“Jean-Baptiste is an experienced leader who has spent his career helping to build successful biopharmaceutical companies. He brings extensive experience in guiding companies through strategic business development initiatives, and understands how to navigate the changing dynamics and complexities of our industry,” said AGC Biologics Chief Executive Officer, Patricio Massera. “We are excited to have him on our global leadership team as our new CBO.  We look forward to leveraging his experience as we continue to innovate and realize the full potential of our development and manufacturing capabilities.”
 
Mr. Agnus brings more than 20 years of experience in biopharmaceuticals and contract development and manufacturing. He joins the company from Ajinomoto Bio-Pharma Services, where he led the company’s strategic vision of its worldwide sales and marketing activities. Prior to that, he worked for 13 years at Novasep, and held a number of business development leadership roles with increasing responsibility both in Europe and the U.S.  Most recently at Novasep, Mr. Agnus served as Head of Sales & Business Development North America, where he led both small molecule API and biologics contract manufacturing services.
 
Mr. Agnus joins the company at a critical time with record-level growth over the last several years. The company invested in expanding its services and capabilities in the cell and gene therapy space, and now has a network of sites on three continents that support the needs of biologics and cell and gene therapeutics developers.